Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancer

Background: Androgen deprivation therapy (ADT) can lead to metabolic syndrome (MS) and is implicated in ADT-resistance. Metformin showed antineoplastic activity through mTOR inhibition secondary AMPK-activation. Materials and Methods: To investigate whether metformin mitigated ADT-related MS, we con...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahalingam, Devalingam, Hanni, Salih, Serritella, Anthony V., Fountzilas, Christos, Michalek, Joel, Hernandez, Brian, Sarantopoulos, John, Datta, Paromitta, Romero, Ofelia, Pillai, Sureshkumar Mulampurath Achutan, Kuhn, John, Pollak, Michael, Thompson, Ian M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2023
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278660/
https://www.ncbi.nlm.nih.gov/pubmed/37335291
http://dx.doi.org/10.18632/oncotarget.28458

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278660/
https://www.ncbi.nlm.nih.gov/pubmed/37335291
http://dx.doi.org/10.18632/oncotarget.28458

Ejemplares similares